Published in PLoS One on October 07, 2015
An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom (1994) 45.51
The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res (2012) 13.14
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials (2005) 11.01
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A (2008) 5.76
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol (2013) 2.54
Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev (2010) 2.53
Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev (2011) 2.41
The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci (2007) 2.22
Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano (2014) 2.17
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target (2002) 2.02
Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol (2010) 2.00
Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano (2011) 1.90
Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci (2007) 1.77
The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials (2008) 1.68
Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta (2010) 1.48
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J Control Release (2012) 1.41
Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging (1991) 1.34
The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomedicine (2013) 1.25
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv (2011) 1.23
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials (2009) 1.19
Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol (2011) 1.16
Protein corona composition of superparamagnetic iron oxide nanoparticles with various physico-chemical properties and coatings. Sci Rep (2014) 1.06
Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release (2010) 1.05
Surface coatings shape the protein corona of SPIONs with relevance to their application in vivo. Langmuir (2012) 0.99
Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. Toxicol Appl Pharmacol (2009) 0.92
Protein corona affects the relaxivity and MRI contrast efficiency of magnetic nanoparticles. Nanoscale (2013) 0.86
Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. Nanomedicine (2014) 0.85
No king without a crown--impact of the nanomaterial-protein corona on nanobiomedicine. Nanomedicine (Lond) (2015) 0.84
It takes two to tango: Understanding the interactions between engineered nanomaterials and the immune system. Eur J Pharm Biopharm (2015) 0.83
Bridge over troubled waters: understanding the synthetic and biological identities of engineered nanomaterials. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.81
A novel prefractionation method combining protein and peptide isoelectric focusing in immobilized pH gradient strips. J Proteome Res (2012) 0.78
Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum. Nanomedicine (2014) 0.85
Comprehensive In Vitro Toxicity Testing of a Panel of Representative Oxide Nanomaterials: First Steps towards an Intelligent Testing Strategy. PLoS One (2015) 0.80
Skeletal Mineralization Deficits and Impaired Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1(-/-) and Phospho1/Pi t1 Double-Knockout Mice. J Bone Miner Res (2016) 0.76
Nanodrugs to target articular cartilage: An emerging platform for osteoarthritis therapy. Nanomedicine (2015) 0.76
Fibrillar vs crystalline nanocellulose pulmonary epithelial cell responses: Cytotoxicity or inflammation? Chemosphere (2016) 0.75
Transcriptional profiling reveals gene expression changes associated with inflammation and cell proliferation following short-term inhalation exposure to copper oxide nanoparticles. J Appl Toxicol (2017) 0.75